

# A novel test (RT-QuIC) to differentiate between two types of REM Behavioural Disorder (RBD) - pRBD (which is a potential indicator of future development of Parkinson's Disease) and iRBD (which is not thought to be)

<b>Submission date</b> 07/01/2020	<b>Recruitment status</b> Stopped	<input checked="" type="checkbox"/> Prospectively registered
<b>Registration date</b> 06/02/2020	<b>Overall study status</b> Stopped	<input type="checkbox"/> Protocol
<b>Last Edited</b> 17/10/2022	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Rapid Eye Movement Sleep Behaviour Disorder (RBD) is a sleep disorder in which people act out their dreams. Previous studies have found a high conversion rate from RBD to subsequent neurodegenerative disease, with the majority of patients developing one of the  $\alpha$ -synucleinopathies (Parkinson's disease, multiple system atrophy, Lewy body dementia). As not all RBD patients go on to develop a neurodegenerative disease (40 - 80.8% in 16 to 25 years of follow-up), and RBD only presents as a comorbidity in a percentage of patients with  $\alpha$ -synucleinopathies (30% of Parkinson's disease patients have RBD), it is important to identify factors which robustly provide prognostic data on the clinical course of RBD. The aim of this study is to develop and validate a test for the detection of pathological protein ( $\alpha$ -syn RT-QuIC) that can be used to differentiate between cases of RBD that subsequently progress to a neurodegenerative disorder such as Parkinson's disease and those that do not.

### Who can participate?

Patients aged over 18 with a diagnosis of RBD

### What does the study involve?

All data is collected in one 90-minute appointment, which takes place at the Wellcome Trust Clinical Research Facility (WTCRF) at either Royal Infirmary of Edinburgh or Western General Hospital Edinburgh. The appointment involves a clinical examination and interview, blood sampling and cerebrospinal fluid (CSF) sampling via lumbar puncture. Participants are interviewed with regards to their lifestyle, medical history and comorbidities. Participants are asked to fill out sleep diaries and questionnaires relating to their sleep. All patients are examined clinically regarding motor function and anosmia. Markers of autonomic dysfunction

are also tested for using simple techniques such as an orthostatic standing test. Any individuals who have already developed PD are interviewed with regards to their neurodegenerative presentation, e.g. response to drug treatment.

What are the possible benefits and risks of participating?

Whilst there is no direct benefit to the individual participant, their participation in the study will help to develop a test which may benefit many other patients with RBD in the future. Time burden to the patient is minimal, with only a single 90-minute study visit required. Blood sampling is generally well-tolerated. Minor discomfort and bruising may occur at the needle site but should self-resolve quickly. Some individuals may feel dizzy or faint, and can lie down during the procedure. A lumbar puncture is generally a safe procedure and serious side effects are uncommon. The most common side effects include headaches, which can last for up to a week and can be relieved using over-the-counter painkillers, and swelling and lower back pain where the needle was inserted, which should get better after a few days and is normally nothing to worry about. The questionnaires used contain personal questions which some individuals may find intrusive or uncomfortable to answer, though all information is required purely to make a complete clinical assessment.

Where is the study run from?

University of Edinburgh/NHS Lothian Royal Infirmary (UK)

When is the study starting and how long is it expected to run for?

January 2020 to September 2023 (updated 21/04/2020, previously: June 2023)

Who is funding the study?

Weston Brain Institute (UK)

Who is the main contact?

Dr Renata Riha

rriha1@staffmail.ed.ac.uk

## Contact information

**Type(s)**

Public

**Contact name**

Mr Steven Williams

**Contact details**

Chancellors Building

Room 305

49 Little France Crescent

Edinburgh

United Kingdom

EH16 4SB

+44 (0)7903029892

picklish@hotmail.com

**Type(s)**

Scientific

**Contact name**

Dr Renata Riha

**Contact details**

Chancellors Building  
Room 305  
49 Little France Crescent  
Edinburgh  
United Kingdom  
EH16 4SB  
+44 (0)131 242 3882  
rriha1@staffmail.ed.ac.uk

**Additional identifiers****Clinical Trials Information System (CTIS)**

Nil known

**ClinicalTrials.gov (NCT)**

Nil known

**Protocol serial number**

Funder's Reference Number - 16021036.1

**Study information****Scientific Title**

Establishing alpha-synuclein Real Time - Quaking Induced Conversion (RT-QuIC) assay as a diagnostic technique in REM sleep behaviour disorder (RBD)

**Acronym**

RTQUIC&RBD

**Study objectives**

The researchers hypothesise that a real-time quaking induced conversion assay for the detection of pathological alpha-synuclein ( $\alpha$ -syn RTQuIC) can be used to differentiate between cases of idiopathic REM-sleep behaviour disorder (RBD) and RBD that is symptomatic of prodromal  $\alpha$ -synucleinopathies. With a patient sample size of  $n=125$ , this multicentre study will be the largest analysis of CSF  $\alpha$ -synuclein in RBD patients to date. In line with The National CJD Research & Surveillance Unit (NCJDRSU)'s recent inclusion of a positive RT-QuIC for pathological prion protein in the diagnostic criteria for Creutzfeldt-Jakob Disease (CJD), the researchers aim to deploy this novel method to establish it as an accurate research and diagnostic resource in the assessment and prognosis of RBD. This research is transformative and has the potential to change practice. Currently, there is no simple method with high sensitivity and specificity available which can identify patients who will go on to develop an  $\alpha$ -synucleinopathy. Clinical assessment of a panel of markers (e.g. Postuma et al. 2015) are time-consuming and impractical in normal clinical settings, with the majority of patients presenting to sleep physicians, geriatricians, and non-specialised neurology clinics, both publicly and privately. This has a major impact on counselling strategies for RBD patients, appropriate follow-up, trials of novel

neuroprotective agents in alpha-synucleinopathies before full-blown phenotype is manifest and enhancing understanding of pathways involved in RBD out-with the dopaminergic system. RBD is a common, sometimes fatal disease (through injury to self/others) and treatments are indiscriminate regarding aetiology with limited evidence-base. A simple test using CSF (analogous to measuring CSF-orexin levels to diagnose narcolepsy+cataplexy) with high sensitivity and specificity is ideal. Thus, the researchers believe that the central thesis of their work will not only inform subsequent behavioural, genetic and neuroimaging characterisation of their established RBD cohort, but will also translate the  $\alpha$ -syn RT-QuIC concept into evidence-based and effective clinical practice.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 23/03/2020, South East Scotland Research Ethics Committee 1 (NHS Lothian, Waverley Gate, 2 - 4 Waterloo Place, Edinburgh, EH1 3EG, UK; +44 (0)131 465 5473; Sandra.Wyllie@nhslothian.scot.nhs.uk), ref: DL/20/ES/0032

### **Study design**

Cross-sectional multicentre study

### **Primary study design**

Observational

### **Study type(s)**

Screening

### **Health condition(s) or problem(s) studied**

REM behavioural disorder and Parkinson's disease

### **Interventions**

This is a cross-sectional, multi-centre study using the CSF of patients with RBD which may or may not develop into a neurodegenerative disease, as well as patients with RBD who have already developed an  $\alpha$ -synucleinopathy. The proposed study length is 3 years (36 months). Participant involvement will be approximately 30 months from receipt of invitation letter to dissemination of results. The researchers envisage ongoing follow-up of this group of patients into the future to assess for development of a  $\alpha$ -synucleinopathy to further confirm the utility of this technique in day-to-day clinical practice.

Participants will be recruited from sleep clinics and existing RBD patient cohort databases under the care of the Department of Sleep Medicine, Royal Infirmary of Edinburgh and the Behavioural Sleep Medicine Department, Ninewells Hospital, Dundee. Together, these departments have an unselected RBD cohort of approximately 250 patients, from which the researchers aim for a sample size of 125 patients.

Participants who consent to participate will be invited to a single, 90 minute, appointment at the clinical research facility (CRF) at either the Royal Infirmary of Edinburgh or Western General Hospital, Edinburgh. Participants will be interviewed with regards to their lifestyle and medical history. They will be asked to fill out sleep diaries and questionnaires relating to their sleep and will be examined clinically for possible symptoms of PD and, in individuals who have already been diagnosed with PD, their response to drug treatment. A 9 ml blood sample will be collected

as part of clinical evaluation. During the lumbar puncture, 1.5 ml of CSF will be collected. The samples will be stored at -80C prior to analysis.

Participants will be observed for the duration of the trial (36 months), and further funding sought to continue long-term follow-up of RBD cohort participants.

### **Intervention Type**

Other

### **Primary outcome(s)**

Positive/negative (binary) result from the  $\alpha$ -syn RT-QuIC assay. A positive output confirms the presence of pathological  $\alpha$ -synuclein within the CSF. Measured using lumbar puncture to obtain CSF at a single trial visit.

### **Key secondary outcome(s)**

All measures will take place at the patient's only trial visit:

1. Screening for co-morbidities using a medical history questionnaire
2. Screening for REM Behavioural disorder with the RBDQ-HK questionnaire
3. Excessive daytime sleepiness assessed using the Epworth Sleepiness Scale
4. Sleep pattern assessed using a sleep diary
5. Stressful events that might cause illnesses assessed using the Holmes and Rahe stress scale
6. Orthostatic hypotension assessed using the Orthostatic Standing Test
7. Clinical rating scale for Parkinson's disease using the MDS-UPDRS questionnaire
8. Venepuncture to obtain 9 ml of blood for future genetic testing in follow-up study

### **Completion date**

01/09/2023

### **Reason abandoned (if study stopped)**

Lack of staff/facilities/resources

## **Eligibility**

### **Key inclusion criteria**

1. Diagnosis of RBD based on International Classification of Sleep Disorders 3rd Edition (ICSD-3) criteria
2. Aged 18 years or over
3. Willing and able to give written informed consent and comply with protocol

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. RBD secondary to medication or withdrawal state
2. <18 years old
3. Unwilling or unable to give written informed consent or comply with protocol
4. Contraindication to lumbar puncture procedure (e.g. patients taking Warfarin)

**Date of first enrolment**

01/10/2021

**Date of final enrolment**

01/12/2022

**Locations****Countries of recruitment**

United Kingdom

Scotland

**Study participating centre****NHS Lothian**

Waverley Gate  
2-4 Waterloo Place  
Edinburgh  
United Kingdom  
EH1 3EG

**Study participating centre****NHS Tayside**

Ninewells Hospital and Medical School  
James Arrott Drive  
Dundee  
United Kingdom  
DD1 9SY

**Study participating centre****The University of Edinburgh**

The National Creutzfeldt-Jakob Disease Research and Surveillance Unit  
Brian Matthews Building  
Western General Hospital

Edinburgh  
United Kingdom  
EH4 2XU

## Sponsor information

**Organisation**  
ACCORD

## Funder(s)

**Funder type**  
Research organisation

**Funder Name**  
Weston Brain Institute

## Results and Publications

### Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date

### IPD sharing plan summary

Data sharing statement to be made available at a later date

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No